| Authors: |
Simmonds NJ; Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom. Electronic address: nicholasjames.simmonds@nhs.net., Charman SC; Cystic Fibrosis Trust, London, United Kingdom., Wosniok J; Interdisciplinary Center for Clinical Trials Mainz, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany., Haugh C; Cystic Fibrosis Trust, London, United Kingdom., Santoro D; Global Clinical Development, Chiesi Farmaceutici S.p.A., Parma, Italy., Fiorini S; Global Regulatory Affairs and Patient Safety, Chiesi Farmaceutici S.p.A., Parma, Italy., Charretier R; Global Clinical Development, Chiesi SAS, Paris, France., Sanchez C; Global Clinical Development, Chiesi Farmaceutici S.p.A., Parma, Italy., Procaccianti C; Global Medical Affairs, Chiesi Farmaceutici S.p.A., Parma, Italy., Naehrlich L; Department of Pediatrics, Justus-Liebig- University Giessen, Giessen, Germany. |
